CSF3 and neutropenia: However, a 25% dose reduction and the G-CSF administration is recommended in patients experiencing G4 neutropenia lasting ≥ 7 days, G febrile neutropenia, or a delay of the next scheduled dose because of G 3-4 neutropenia by 2 or 3 weeks before recovery to grade 1 [44].